Newcells Biotech (Axol Bioscience)

Newcells Biotech Ltd, founded in 2014, is a promising player in the Biotechnology and Health Care sectors, headquartered in the United Kingdom. The company prides itself on its slogan: "In vitro models to accelerate clinical translation." They specialize in creating cutting-edge predictive in vitro models that aid in the critical evaluation of drug safety and efficacy, thereby streamlining drug discovery and development processes.

Newcells Biotech offers innovative tissue model platforms that simulate in vivo physiology, such as the retina, kidney, and lung, thus removing uncertainty from drug development. Their solutions are particularly valuable for reducing drug attrition by providing reliable preclinical data.

Recently, Newcells Biotech secured a £2.35M Venture Round from investors including Northstar Ventures, North East Innovation Fund, and Mercia Ventures. This influx of capital underscores confidence in their capability to enhance drug development efficiency, potentially saving costs and lives.